RMD financials
ResMed Inc. · end-of-day data as of Oct 16, 2026
ResMed Inc.
$238.97+22.7%
Buy · 20 analystsPT $247.91 +3.7%
RMD reported revenue of $1.46B for the quarter ended Jun 30, 2026 (Q4 FY2026), up 8.6% from a year earlier. It posted diluted EPS of $2.64, free cash flow of $1.65B and a net margin of 26.2%.
Valuation
- P/E23.0x
- P/E vs own-0.4%
- P/E vs sector-18.4%
- FCF yield+8.6%
- Market cap$33.61B
Quarterly results
Q4 FY2026: Revenue +8.6% year over year, free cash flow 112.7% of revenue, operating margin 30.7%.
RevenueFree cash flow
| Q4 FY2026 | Jun 30, 2026 | $1.46B | 2.64 | $1.65B | 58.8% | 30.7% | 26.2% |
| Q3 FY2026 | Mar 31, 2026 | $1.43B | 2.71 | $520M | 62.2% | 34.9% | 27.9% |
| Q2 FY2026 | Dec 31, 2025 | $1.42B | 2.68 | $305M | 62.2% | 35.0% | 27.6% |
| Q1 FY2026 | Sep 30, 2025 | $1.34B | 2.37 | $414M | 61.5% | 33.4% | 26.1% |
| Q4 FY2025 | Jun 30, 2025 | $1.35B | 2.58 | $508M | 60.8% | 33.7% | 28.2% |
| Q3 FY2025 | Mar 31, 2025 | $1.29B | 2.48 | $555M | 59.3% | 33.0% | 28.3% |
| Q2 FY2025 | Dec 31, 2024 | $1.28B | 2.34 | $290M | 58.6% | 32.5% | 26.9% |
| Q1 FY2025 | Sep 30, 2024 | $1.22B | 2.11 | $306M | 58.6% | 31.6% | 25.4% |
| Q4 FY2024 | Jun 30, 2024 | $1.22B | 1.98 | $414M | 57.6% | 31.2% | 23.9% |
| Q3 FY2024 | Mar 31, 2024 | $1.2B | 2.04 | $379M | 56.9% | 31.3% | 25.1% |
| Q2 FY2024 | Dec 31, 2023 | $1.16B | 1.42 | $249M | 57.6% | 23.7% | 18.0% |
| Q1 FY2024 | Sep 30, 2023 | $1.1B | 1.49 | $245M | 54.4% | 26.2% | 19.9% |